GLP-3 RTA [Triple G] – 20mg

GLP-3 RTA (Triple G) is a triple incretin receptor agonist simultaneously targeting glucagon like peptide-1 (GLP-1), glucose dependent insulinotropic polypeptide (GIP), and glucagon receptors. The most advanced incretin based research compound in CSD’s metabolic peptide range. Hudson Science’s 20mg formulation delivers the second lowest concentration presentation across CSD’s full GLP-3 RTA range as a lyophilized vial, sitting above the 30mg entry point and providing a stepped concentration increase for dose escalation research protocols examining triple incretin receptor co activation across a defined concentration ladder.

The 20mg concentration occupies a specific position in the GLP-3 RTA research series that warrants distinction from the 30mg variant. Where the 30mg format serves as the lowest reference point for initial compound evaluation and baseline pharmacological response characterization, the 20mg format. Being lower in concentration is particularly suited to the earliest stages of dose response mapping where sub threshold and near threshold receptor activation research is the primary variable. This makes the 20mg presentation a valuable tool for researchers establishing the full lower bounds of the triple incretin receptor co activation dose response curve before progressing through the 30mg, 40mg, 50mg, and 60mg concentration points available across CSD’s complete GLP-3 RTA range.

The triple receptor mechanism remains consistent across all GLP-3 RTA presentations. GLP-1 receptor activation drives glucose dependent insulin secretion, glucagon suppression, and central nervous system satiety signaling. GIP receptor activation contributes complementary insulinotropic activity alongside adipose tissue metabolic and bone turnover research dimensions. Glucagon receptor co activation adds hepatic glucose output regulation, thermogenic energy expenditure stimulation, and lipolytic activity, producing a synergistic metabolic response that distinguishes triple incretin agonism from the dual GIP/GLP-1 mechanism of CSD’s GLP-2 TZ and GLP-2 TRZ listings and the pure GLP-1 selectivity of the Semaglutide pen.

Hudson Science formulations are stocked by Canada Steroid Depot following the same rigorous third party lab verification process applied to every product in our range. Each batch is tested for concentration accuracy and purity before being made available, with COA documentation available on request. CSD’s sourcing standards apply uniformly across all manufacturers we carry, and Hudson Science’s GLP-3 RTA 20mg meets those standards consistently. All orders ship discreetly across Canada in plain, unmarked packaging with no identifying information on the exterior.

Reconstitute with bacteriostatic water prior to use. Store lyophilized peptide at 2–8°C away from direct light. Once reconstituted refrigerate and use within 28 days. Intended for research purposes only.

Commonly researched alongside dual incretin agonist compounds in comparative receptor pathway and metabolic activity studies. Browse CSD’s full peptide range for complete sourcing.